In Vivo Evidence for Low Striatal Vesicular Monoamine Transporter 2 (VMAT2) Availability in Cocaine Abusers

Dr. Narendran's research group at the University of Pittsburgh has contractual research agreements with Sunovion and GlaxoSmithKline. Dr. Daley receives grant support from NIH/NIDA for research, receives royalties for written materials for professionals and individuals in recovery from several publishers (Oxford University Press; Hazelden Educational Materials; Daley Publications, and Independence Press), and receives royalties from Distance Learning for an online course based on his work. Dr. Mathis reports royalties from a license agreement between the University of Pittsburgh and GE Healthcare for amyloid imaging technology not related to this work; he has been a consultant for Elan, GE Healthcare, IBA, Janssen, and Wyeth/Pfizer. Dr. Frankle has been a consultant for Ono and Sunovion. The remaining authors report no financial relationships with commercial interests.Supported by award R03 DA-024704 from the National Institute on Drug Abuse (NIDA) under the American Reinvestment and Recovery Act of 2009 and by award CTSA-UL1 RR-024153 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIDA or the National Institutes of Health.